Featured news | Nanologica

Nanologica AB (publ) has decided to focus on Chromatography and the management team is adapted to reflect the new business focus.

8 May, 2023

In order to create the best conditions for success in preparative chromatography, the company’s operations are focused on Chromatography and the Drug Development operations are down-prioritized and placed in subsidiaries for future opportunities. The management team is adapted to reflect this and CSO Gary Pitcairn and VP Drug Development Ulf Ericsson will leave the company for new opportunities. “ Our work within Drug Development has reached a point where continued development is very resource-intensive and we

NANOLOGICA’S PRODUCT WITHIN PREPARATIVE CHROMATOGRAPHY REACHES QUALITY REQUIREMENTS

3 May, 2023

After successfully implementing fine-tuning in production, Nanologica’s product now meets the company’s own requirements for quality in all evaluated parameters. The company is therefore continuing to formally approve products to be able delivery to customers progressively. ”After making further fine-tunings in one of the production steps, we now have a product that we are satisfied with and that we can proudly deliver to customers. Finally! This means that we now can move on with the

Vd Andreas Bhagwani presenterar Nanologicas delårsrapport för Q1 2023

28 April, 2023

Nanologica’s Annual Report 2022 Published

24 March, 2023

Nanologica AB’s annual report for 2022 is now published on the company’s website. The annual report in Swedish, and an English translation, is available on www.nanologica.com as a pdf. The annual report in Swedish is also available in the European Single Electronic Format (ESEF). Swedish: https://nanologica.com/category/finansiella-rapporter/ English translation: https://nanologica.com/category/financial-reports/ For further information, please contact: Johanna Johansson, Director IR, Communications and Marketing Ph: +46 72 211 21 90 or e-mail: ir@nanologica.com This information is information that

Vd Andreas Bhagwani presenterar fjärde kvartalet 2022

10 February, 2023

CEO Andreas Bhagwani presents Nanologica’s Interim Report Q3 2022

11 November, 2022

About us

Nanologica is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. Nanologica’s products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company’s mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments. The company is headquartered in Södertälje and Nanologica’s share (NICA) is listed for trading on Nasdaq Stockholm Main Market.